- Syngene International has opened a dedicated peptide laboratory in Bengaluru and integrated advanced automation in Hyderabad to accelerate drug discovery and development.
- Automation in DMPK and Direct-to-Biology workflows reduces turnaround times, improves cost efficiency by 30%, and increases sample capacity.
Syngene International, a global contract research, development, and manufacturing organization (CRDMO), has announced upgrades at its Bengaluru and Hyderabad sites to enhance drug discovery and development capabilities. The investments include a dedicated peptide laboratory and automation across DMPK and Direct-to-Biology (D2B) workflows, aimed at accelerating therapeutic innovation and improving operational efficiency.
The Bengaluru peptide laboratory is designed to synthesise a wide variety of molecules, including linear peptides, cyclic peptides, and peptide-drug conjugates, with synthesis scale-up to 800 mmol. Six automated peptide synthesizers equipped with robotic arms, coupled with integrated purification and quality control systems, allow for faster project completion while maintaining consistent results.
In Hyderabad, automation has been integrated into DMPK operations, reducing sample preparation turnaround from five days to three and improving cost efficiency by 30%. The enhancements also triple sample capacity, providing clients with faster access to critical data. The D2B platform accelerates hit-to-lead and lead optimisation, saving at least a week for small compound sets and several weeks for larger sets.
“The establishment of our dedicated peptide laboratory is another strategic step forward. Peptides are increasingly vital in therapeutic development and this specialised facility enables us to support our partners with end-to-end capabilities—from synthesis and purification to characterisation and early-stage development. By combining automation with scientific expertise, we are creating a robust platform to accelerate therapeutic innovation and deliver greater value to our clients.”
Peter Bains, Managing Director and CEO of Syngene International
With these site upgrades, Syngene International has strengthened its end-to-end CRDMO platform, connecting discovery to downstream development and manufacturing. The combined capabilities of automation and scientific expertise reinforce the company’s collaborative model, helping clients bring novel therapies to market faster and more efficiently.
